|
|
|
题名
|
作者
|
年代
|
出处
|
被引量
|
| 1 | Serum p53 antibodies incorrelation to other biologieal parameters of breast cancer显示文摘 | Sangrajran S Arpornwirat W Cheirsilpa A | 2003 | Cancer Detect Prev2003，27，3： | 1 |
| 2 | Serum p53 antibodies in correlation to other biological parameters of breast cancer显示文摘 | Sangrajrang S Arpomwirat W Cheirsilpa A | | 0，，： | 1 |
| 3 | High-dosemitomycin C: activity in hepatocellular carcinoma 显示文摘 | Cheirsilpa A Leelasethakul S Auethaveekiat V | 1989 | CancerChemother Pharmacol1989，24，1： | 1 |
| 4 | Comparison of ramosetron and granisetron for the prevention of acute and delayed emesis in cisplatin-based chemotherapy: a randomized controlled trial 显示文摘 | Cheirsilpa A Sinthusake T Songsakkaesorn A | 2005 | Jpn J Clin Oncol2005，35，12： | 1 |
| 5 | Cetuximab plus irinotecan in pretreated metastatic colorectal cancer patients:The ELSIE study显示文摘AIM:To evaluate the efficacy and safety of cetuxim-ab plus irinotecan in irinotecan-refractory metastatic colorectal cancer (mCRC) patients from South-East Asia and Australia. METHODS:In this open-label,phase Ⅱ study,the main eligibility criteria were epidermal growth factor receptor-positive mCRC with progressive disease within 3 mo of an irinotecan-based regimen as the most recent chemotherapy. Patients received cetuximab 400 mg/m2 initially,then 250 mg/m2 every week,with the same regimen of irinotecan on which the patients had progressed (4 pre-defined regim-ens allowed). The prim-ary objective was evaluation of progression-free survival (PFS) at 12 wk. Secondary objectives included a further investigation of PFS,and an assessment of the overall response rate (ORR),duration of response,time to treatment failure (TTF),overall survival and the safety profile. RESULTS:One hundred and twenty nine patients were enrolled from-25 centers in the Asia-Pacific region and of these 123 received cetuximab plus irinotecan. The most common recent irinotecan regimen used was 180 mg/m2 every 2 wk which had been used in 93 patients (75.6%). The PFS rate at 12 wk was 50% (95% confidence interval (CI,41-59) and m-edian PFS tim-e was 12.1 wk (95% CI:9.7-17.7). The ORR was 13.8% (95% CI:8.3-21.2) and disease control rate was 49.6% (95% CI:40.5-58.8). Median duration of response was 31.1 wk (95% CI:18.0-42.6) and median overall survival was 9.5 mo (95% CI,7.5-11.7). The median TTF was 11.7 wk (95% CI:9.1-17.4). Treatment was generally well tolerated. The most common grade 3/4 adverse events were diarrhea (13.8%),neutropenia (8.9%),rash (5.7%) and vomiting (5.7%).CONCLUSION:In patients from Asia and Australia,this study confirm-s the activity and safety of cetuxim-ab plus irinotecan observed in previous studies in Europe and South America. | Robert Lim Yan Sun Seock-Ah Im Ruey-Kuen Hsieh Tsz Kok Yau Anthony Bonaventura Arkom Cheirsilpa Regina Esser Matthias Mueser Suresh Advani | 2011 | World Journal of Gastroenterology2011，17，14： | 1 |
| 6 | Serum p53 antibodies in correlation to other biological parameters of breast cancer显示文摘 | Sangrajrang S Arpornwirat W Cheirsilpa A | | 0，，03： | 1 |
| 7 | Comparison of ramosetron and granisetron for the prevention of acute and delayed emesis in Cisplatin - based chemotherapy : a randomized controlled trial显示文摘 | Cheirsilpa A Simhusake T Songsakkaesom A | 2005 | Jpn J Clin Oncol2005，35，12： | 1 |
| 8 | Comparison of ramosetron and granisetron for the prevention of acute and delayed emesis in cisplatin -based chemotherapy: a randomized controlled trial 显示文摘 | Cheirsilpa A Sinthusake T Songsakkaesorn A | 2005 | Japanese Journal of Clinical Oncology2005，35，12： | 1 |
| 9 | Serum p53 antibodies in correlation to other biological parameters of breast cancer显示文摘 | SANGRAJRANG S ARPORNWIRAT W CHEIRSILPA A | 2003 | Cancer Detect Prey2003，27，3： | 1 |
| 10 | Serum p53 antibodies in correlation to other biological parameters of breast cancer 显示文摘 | Sangrajrang S Arpomwirat W Cheirsilpa A | 2003 | Cancer Detect Prey2003，27，3： | 1 |
您所在的机构暂未开通此部分的功能，请联系管理员